Response: Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma

“Immunotherapy of myeloma by using immunogenic dead cells seems to be more complex than anticipated.”

We have read with great interest and appreciated the Commentary of Ken Maes and Karine Breckpot pointing out the difficulties to achieve an efficient vaccination using myeloma cells killed by using anti-tumor drugs, in such a way to generate immunogenic corpses able to elicit protective immunity in patients. In this sense, the pioneer studies of De Beck et al. (2018), clearly illustrated the problems to achieve an immunization protocol providing a 100% protection. Although complete protection from myeloma development could not be reached, vaccination with drug-treated myeloma cells induced a delay in tumor progression (De Beck et al., 2018). This relevant work was inadvertently omitted in our previous review on immunogenic cell death (ICD) and immunotherapy of multiple myeloma (Serrano-Del Valle et al., 2019). Moreover, in experiments carried out after the publication of our review, we could not prevent induced myeloma in an immunocompetent mouse model that mimics human myeloma development, by vaccination with apoptotic myeloma cells killed with bona fide ICD inducers, which cause ecto-calreticulin exposure (data not shown). These results also illustrate the inability of current immunization protocols to completely prevent myeloma development, underscoring the problems discussed by Maes and Breckpot (2019). We also agree with these authors on which the ICD-inducing capacities of dying MM cells needs to be better defined to design more efficient, improved immunization protocols in immunocompetent mice as a first step to translate this information to human myeloma therapy.

Statements

Summary

Keywords

immunogenic cell death, multiple myeloma, ER stress, danger-associated molecular pattern, immunotherapy

Citation

Serrano Del Valle A, Anel A, Naval J and Marzo I (2019) Response: Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Front. Cell Dev. Biol. 7:306. doi: 10.3389/fcell.2019.00306

Received

09 October 2019

Accepted

11 November 2019

Published

27 November 2019

Volume

7 - 2019

Edited by

Lawrence H. Boise, Emory University, United States

Reviewed by

Leon Bernal-Mizrachi, Winship Cancer Institute, Emory University, United States

Updates

Check for updates

Copyright

© 2019 Serrano Del Valle, Anel, Naval and Marzo.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Alfonso Serrano Del Valle alfonso__serrano@hotmail.com

This article was submitted to Cell Death and Survival, a section of the journal Frontiers in Cell and Developmental Biology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.